Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.48 |
| ▸ | ILK | Q13418 | 8/20 | 0.48 |
| ▸ | KDM1A | O60341 | 4/20 | 0.39 |
| ▸ | KIT | P10721 | 4/20 | 0.39 |
| ▸ | KDR | P35968 | 3/20 | 0.39 |
| ▸ | FLT1 | P17948 | 2/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.39 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.39 |
| ▸ | PLK4 | O00444 | 1/20 | 0.39 |
| ▸ | CIT | O14578 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | GAK | O14976 | 1/20 | 0.39 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.39 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.39 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.39 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.39 |
| ▸ | BUB1 | O43683 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.39 |
| ▸ | STK17B | O94768 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2047588 | 0.71 | EGFR (0.51) | EGFRILKKDM1AKITKDR | |
| SCHEMBL5359866 | 0.71 | EGFR (0.52) | EGFRILKKDM1AKITKDR | |
| Hydrochloric Acid SCHEMBL4473967 | 0.70 | EGFR (0.52) | EGFRILKKDM1AKITKDR | |
| SCHEMBL8683115 | 0.70 | KDR (0.63) | EGFRILKKDM1AKITKDR | |
| Hydrochloric Acid SCHEMBL8684910 | 0.69 | KDR (0.62) | EGFRILKKDM1AKITKDR | |
| SCHEMBL5665202 | 0.69 | KDR (0.42) | EGFRILKKDM1AKITKDR | |
| SCHEMBL8685042 | 0.68 | EGFR (0.70) | EGFRILKKDM1AKITKDR | |
| Hydrochloric Acid SCHEMBL1507571 | 0.68 | KIT (0.50) | EGFRILKKITKDRGAK | |
| SCHEMBL4558198 | 0.67 | EGFR (0.47) | EGFRILKKDM1AKITKDR | |
| SCHEMBL3795753 | 0.67 | EGFR (0.47) | EGFRILKKDM1AKITKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 240 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080206257-A1 | Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor | PFIZER INC. | 2008-08-28 | — | — | US | claimed |
| EP-1276496-B1 | COMBINED TREATMENT WITH KERATINOCYTE GROWTH FACTOR AND EPIDERMAL GROWTH FACTOR INHIBITOR | PFIZER PROD INC (US) | 2005-06-15 | — | — | EP | claimed |
| US-20040071697-A1 | Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor | PFIZER PRODUCTS INC. | 2004-04-15 | — | — | US | claimed |
| JP-2003527437-A | — | — | 2003-09-16 | — | — | JP | claimed |
| EP-1276496-A2 | COMBINED TREATMENT WITH KERATINOCYTE GROWTH FACTOR AND EPIDERMAL GROWTH FACTOR INHIBITOR | Pfizer Products Inc. (US) | 2003-01-22 | — | — | EP | claimed |
| US-20020061304-A1 | Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor | PFIZER PRODUCTS INC. & OSI PHARMACEUTICALS, INC. | 2002-05-23 | — | — | US | claimed |
| WO-2001070255-A2 | COMBINED TREATMENT WITH KERATINOCYTE GROWTH FACTOR AND EPIDERMAL GROWTH FACTOR INHIBITOR | PFIZER PRODUCTS, INC. (US) | 2001-09-27 | — | — | WO | claimed |
| CN-118159538-A | Pharmaceutical composition containing MET receptor tyrosine kinase inhibitor and application thereof | 上海海和药物研究开发股份有限公司 | 2024-06-07 | — | — | CN | disclosed |
| US-20230220491-A1 | THERAPEUTIC, DIAGNOSTIC, AND PROGNOSTIC METHODS FOR CANCER | GENENTECH INC (US) | 2023-07-13 | — | — | US | disclosed |
| WO-2023078408-A1 | PHARMACEUTICAL COMBINATION CONTAINING MET RECEPTOR TYROSINE KINASE INHIBITOR AND USE THEREOF | 上海海和药物研究开发股份有限公司 | 2023-05-11 | — | — | WO | disclosed |
| US-11261498-B2 | Methods for diagnosing and treating cancer | GENENTECH, INC. (US) | 2022-03-01 | — | — | US | disclosed |
| EP-3487497-B1 | COMBINATIONS COMPRISING AR ANTAGONISTS OR INHIBITORS FOR USE IN TREATING GLIOBLASTOMA | HADASIT MED RES SERVICE (IL) | 2021-09-08 | — | — | EP | disclosed |
| US-20200283856-A1 | PROGNOSTIC AND DIAGNOSTIC METHODS FOR COLORECTAL CANCER | UNIV CALIFORNIA (US) | 2020-09-10 | — | — | US | disclosed |
| US-20050272738-A1 | Combined treatment with oxaliplatin and an epidermal growth factor receptor kinase inhibitor | OSI PHARMACEUTICALS, INC. | 2005-12-08 | — | — | US | disclosed |
| US-20050272737-A1 | Combined treatment with irinotecan and an epidermal growth factor receptor kinase inhibitor | CHEN JIANPING | 2005-12-08 | — | — | US | disclosed |
| EP-1276496-B1 | COMBINED TREATMENT WITH KERATINOCYTE GROWTH FACTOR AND EPIDERMAL GROWTH FACTOR INHIBITOR | PFIZER PROD INC (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040071697-A1 | Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor | PFIZER PRODUCTS INC. | 2004-04-15 | — | — | US | disclosed |
| EP-1276496-A2 | COMBINED TREATMENT WITH KERATINOCYTE GROWTH FACTOR AND EPIDERMAL GROWTH FACTOR INHIBITOR | Pfizer Products Inc. (US) | 2003-01-22 | — | — | EP | disclosed |
| US-20020061304-A1 | Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor | PFIZER PRODUCTS INC. & OSI PHARMACEUTICALS, INC. | 2002-05-23 | — | — | US | disclosed |
| WO-2001070255-A2 | COMBINED TREATMENT WITH KERATINOCYTE GROWTH FACTOR AND EPIDERMAL GROWTH FACTOR INHIBITOR | PFIZER PRODUCTS, INC. (US) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11261498-B2 | Methods for diagnosing and treating cancer | ERBB2, EGFR, ERBB3 | EGFR 2/4885ILK 4123/4885KDM1A 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.